Cochlear toxicity of butikacin (UK-18,892), a new semisynthetic aminoglycoside antibiotic, in guinea pigs.
AUTOR(ES)
Carter, A J
RESUMO
The cochleotoxic potential of butikacin (UK-18,892), a new semisynthetic aminoglycoside, has been evaluated in neonatal guinea pigs in comparison with amikacin, gentamicin, and kanamycin A. All compounds produced a dose-related increase of the mean threshold sound intensity required to elicit Preyer's reflex. Butikacin produced a similar level of cochlear toxicity to that of kanamycin A, but tended to be less cochleotoxic than amikacin. Gentamicin was the least cochleotoxic.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=352861Documentos Relacionados
- In Vitro Studies with UK-18,892, a New Aminoglycoside Antibiotic
- UK-18,892: Resistance to Modification by Aminoglycoside-Inactivating Enzymes
- UK-18892, a New Aminoglycoside: An In Vitro Study
- Comparative pharmacokinetics of aminoglycoside antibiotics in guinea pigs.
- Aminoglycoside binding sites in the inner ears of guinea pigs.
